Liquid biopsy may help identify which patients with non-small cell lung cancer will benefit most from radiation


Liquid biopsy is showing promise in identifying the patients with non-small cell lung cancer who will benefit the most from radiation. This non-invasive technique involves analyzing circulating tumor DNA in the blood to determine the genetic makeup of the tumor. The study suggests that patients whose liquid biopsy results show a high level of tumor DNA may respond better to radiation therapy. This personalized approach to treatment could help improve outcomes for lung cancer patients. The use of cookies on the website is also mentioned, indicating the site’s data collection and privacy policy.

Source link

error: Content is protected !!